Literature DB >> 9573077

Validation of a volunteer model of cholera with frozen bacteria as the challenge.

D A Sack1, C O Tacket, M B Cohen, R B Sack, G A Losonsky, J Shimko, J P Nataro, R Edelman, M M Levine, R A Giannella, G Schiff, D Lang.   

Abstract

To evaluate a standardized inoculum of Vibrio cholerae for volunteer challenge studies, 40 healthy adult volunteers were challenged at three different institutions with a standard inoculum prepared directly from vials of frozen, virulent, El Tor Inaba V. cholerae N16961, with no further incubation. Groups of 5 volunteers, with each group including 2 volunteers with blood group O, were given a dose of 10(5) CFU, and 34 of the 40 volunteers developed diarrhea (mean incubation time, 28 h). Transient fevers occurred in 15 (37.5%) of the volunteers. V. cholerae was excreted by 36 of 40 volunteers. Five additional volunteers received 10(4) CFU, and four developed diarrhea but with a lower average purging rate than required for the model. Of the 40 volunteers, 37 developed rises in their vibriocidal and antitoxin titers similar to those in previous groups challenged with freshly harvested bacteria. We conclude that challenge with frozen bacteria results in a reproducible illness similar to that induced by freshly harvested bacteria. Use of this model should minimize differences in attack rates or severity when groups are challenged at different times and in different institutions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9573077      PMCID: PMC108151          DOI: 10.1128/IAI.66.5.1968-1972.1998

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  17 in total

1.  ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy.

Authors:  J D Clemens; D A Sack; J R Harris; J Chakraborty; M R Khan; S Huda; F Ahmed; J Gomes; M R Rao; A M Svennerholm
Journal:  J Infect Dis       Date:  1989-04       Impact factor: 5.226

2.  Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh.

Authors:  D A Sack; J D Clemens; S Huda; J R Harris; M R Khan; J Chakraborty; M Yunus; J Gomes; O Siddique; F Ahmed
Journal:  J Infect Dis       Date:  1991-08       Impact factor: 5.226

3.  Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.

Authors:  M M Levine; J B Kaper; D Herrington; J Ketley; G Losonsky; C O Tacket; B Tall; S Cryz
Journal:  Lancet       Date:  1988-08-27       Impact factor: 79.321

4.  Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a.

Authors:  C O Tacket; B Forrest; R Morona; S R Attridge; J LaBrooy; B D Tall; M Reymann; D Rowley; M M Levine
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

5.  Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin.

Authors:  R E Black; M M Levine; M L Clements; C R Young; A M Svennerholm; J Holmgren
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

6.  Endemic cholera in rural Bangladesh, 1966-1980.

Authors:  R I Glass; S Becker; M I Huq; B J Stoll; M U Khan; M H Merson; J V Lee; R E Black
Journal:  Am J Epidemiol       Date:  1982-12       Impact factor: 4.897

7.  Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera.

Authors:  G A Losonsky; J Yunyongying; V Lim; M Reymann; Y L Lim; S S Wasserman; M M Levine
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

8.  ABO blood groups and cholera.

Authors:  D Barua; A S Paguio
Journal:  Ann Hum Biol       Date:  1977-09       Impact factor: 1.533

9.  Impact of B subunit killed whole-cell and killed whole-cell-only oral vaccines against cholera upon treated diarrhoeal illness and mortality in an area endemic for cholera.

Authors:  J D Clemens; D A Sack; J R Harris; J Chakraborty; M R Khan; B F Stanton; M Ali; F Ahmed; M Yunus; B A Kay
Journal:  Lancet       Date:  1988-06-18       Impact factor: 79.321

10.  Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: application in serodiagnosis and seroepidemiology.

Authors:  M M Levine; C R Young; R E Black; Y Takeda; R A Finkelstein
Journal:  J Clin Microbiol       Date:  1985-02       Impact factor: 5.948

View more
  24 in total

Review 1.  Experimental Helicobacter pylori infection in humans: a multifaceted challenge.

Authors:  P Michetti
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

2.  Cholera: lessons from haiti and beyond.

Authors:  Ana A Weil; Louise C Ivers; Jason B Harris
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

Review 3.  Going against the grain: chemotaxis and infection in Vibrio cholerae.

Authors:  Susan M Butler; Andrew Camilli
Journal:  Nat Rev Microbiol       Date:  2005-08       Impact factor: 60.633

4.  Enterotoxin-specific immunoglobulin E responses in humans after infection or vaccination with diarrhea-causing enteropathogens.

Authors:  F Qadri; M Asaduzzaman; C Wennerås; G Mohi; M J Albert; M Abdus Salam; R B Sack; M Jertborn; J R McGhee; D A Sack; J Holmgren
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 5.  Vaccinology in the era of high-throughput biology.

Authors:  Helder I Nakaya; Bali Pulendran
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-06-19       Impact factor: 6.237

6.  Antimicrobial Resistance Risks of Cholera Prophylaxis for United Nations Peacekeepers.

Authors:  Amber Kunkel; Joseph A Lewnard; Virginia E Pitzer; Ted Cohen
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

7.  The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.

Authors:  Luis García; Manuel Díaz Jidy; Hilda García; Boris L Rodríguez; Roberto Fernández; Gemma Año; Bárbara Cedré; Tania Valmaseda; Edith Suzarte; Margarita Ramírez; Yadira Pino; Javier Campos; Jorge Menéndez; Rodrigo Valera; Daniel González; Irma González; Oliver Pérez; Teresita Serrano; Miriam Lastre; Fernando Miralles; Judith Del Campo; Jorge Luis Maestre; José Luis Pérez; Arturo Talavera; Antonio Pérez; Karen Marrero; Talena Ledón; Rafael Fando
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

8.  Relatedness of Vibrio cholerae O1/O139 isolates from patients and their household contacts, determined by multilocus variable-number tandem-repeat analysis.

Authors:  Emily A Kendall; Fahima Chowdhury; Yasmin Begum; Ashraful I Khan; Shan Li; James H Thierer; Jason Bailey; Kristen Kreisel; Carol O Tacket; Regina C LaRocque; Jason B Harris; Edward T Ryan; Firdausi Qadri; Stephen B Calderwood; O Colin Stine
Journal:  J Bacteriol       Date:  2010-06-28       Impact factor: 3.490

9.  Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines.

Authors:  Clayton Harro; Subhra Chakraborty; Andrea Feller; Barbara DeNearing; Alicia Cage; Malathi Ram; Anna Lundgren; Ann-Mari Svennerholm; August L Bourgeois; Richard I Walker; David A Sack
Journal:  Clin Vaccine Immunol       Date:  2011-08-18

Review 10.  The incubation period of cholera: a systematic review.

Authors:  Andrew S Azman; Kara E Rudolph; Derek A T Cummings; Justin Lessler
Journal:  J Infect       Date:  2012-11-29       Impact factor: 6.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.